Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples